Summary: Diabetic kidney disease (DKD) is a common complication of type 2 diabetes and the most frequent cause of end-stage kidney disease (ESKD) in developed countries. It is strongly associated with cardiovascular disease, which is the cause of death in 40% of patients before they reach ESKD. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the recently developed class of oral anti-hyperglycemic drugs which are gaining considerable interest among diabetologists, cardiologists and nephrologists. In the article, the cardiovascular and renal benefits of this novel class of antidiabetic drugs, as shown in four recent international trials are discussed.